May 20, 2016: Santhera receives FDA Fast Track Designation for Omigapil for the Treatment of Congenital Muscular Dystrophies (CMD) (Santhera Pharmaceuticals Holding AG)

(Source: Santhera Pharmaceuticals Holding AG) 7d047f06-b7e7-4058-84b4-c016cf4b7ec0.pdf Santhera Pharmaceuticals Holding AG Hammerstrasse 49 CH-4410 Liestal / Switzerland Phone +41 61 906 89 50 Fax +41 61 906 89 51 www.santhera.com Santhera receives FDA Fast Track Designation for Omigapil for the Treatment of Congenital Muscular Dystrophies (CMD) Liestal, Switzerland, May 20, 2015 - Santhera Pharmaceuticals (SIX: SANN) announces that it has received Fast Track Designation from the US Food and Drug Administration (FDA) for omigapil for the treatment of congenital muscular dystrophies (CMD). FDA's Fast Track pro- cess is designed to facilitate the development and expedite the review of drugs to...